Familial medullary thyroid carcinoma: Clinical Trials

3 trials for Familial medullary thyroid carcinoma, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

3 completed. 2 Phase 2, 1 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 22Completed 2
Phase 31Completed 1

Follow Familial medullary thyroid carcinoma: new trials by email Literature Review of Familial medullary thyroid carcinoma trials Research Report on Familial medullary thyroid carcinoma

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
An Efficacy Study Comparing ZD6474 to Placebo in Medullary Thyroid Cancer
ZD6474 (Vandetanib) - Thyroid Cancer
Phase 3CompletedGenzyme, a Sanofi Company3312006-11-232025-09-24
Sorafenib Tosylate in Treating Patients With Metastatic, Locally Advanced, or Recurrent Medullary Thyroid Cancer
Sorafenib Tosylate - Hereditary Thyroid Gland Medullary Carcinoma, Locally Advanced Thyroid Gland Medullary Carcinoma
Phase 2CompletedNational Cancer Institute (NCI)212006-11-032024-02-06
A Study To Assess ZD6474 (ZACTIMA™) Monotherapy In Locally Advanced or Metastatic Hereditary Medullary Thyroid Cancer
ZD6474 (vandetanib) - Thyroid Cancer
Phase 2CompletedGenzyme, a Sanofi Company192006-08-012017-01-30

Narrower conditions

Carcinoma, Medullary (3)  ·  Thyroid Neoplasms (2)  ·  Multiple Endocrine Neoplasia Type 2a (1)  ·  Multiple Endocrine Neoplasia Type 2b (1)

Broader conditions

Adenocarcinoma (3)  ·  Carcinoma (3)  ·  Carcinoma, Neuroendocrine (3)  ·  Endocrine Gland Neoplasms (3)  ·  Endocrine System Diseases (3)  ·  Neoplasms (3)  ·  Neoplasms by Histologic Type (3)  ·  Neoplasms by Site (3)  ·  Neoplasms, Ductal, Lobular, and Medullary (3)  ·  Neoplasms, Germ Cell and Embryonal (3)  ·  Neoplasms, Glandular and Epithelial (3)  ·  Neoplasms, Nerve Tissue (3)  ·  Neuroectodermal Tumors (3)  ·  Neuroendocrine Tumors (3)  ·  Head and Neck Neoplasms (2)

Interventions

vandetanib (2)  ·  Sorafenib (1)

Sponsors

Genzyme, a Sanofi Company (2)  ·  National Cancer Institute (NCI) (1)

Countries

United States (3)  ·  Australia (2)  ·  Canada (2)  ·  Italy (2)  ·  Netherlands (2)  ·  Romania (2)  ·  Spain (2)  ·  Switzerland (2)  ·  Austria (1)  ·  Belgium (1)  ·  Brazil (1)  ·  Czechia (1)  ·  Denmark (1)  ·  France (1)  ·  Germany (1)

Top investigators

Bhavana Konda (1)

Results publications

PMID 22025146

NIH funding

2005 (1), N01CM00070 (1), N01CM62207 (1), P30CA016058 (1)